Sun Pharma Financial Statements

Sun Pharma (SUNPHARMA) reported revenue of ₹525.78B in FY2025 with net income of ₹109.29B. Total assets stood at ₹921.01B and free cash flow was ₹119.44B.

Sun Pharma Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		334.98B	386.54B	438.86B	498.51B	525.78B
Cost of Rev. Cost of Revenue		-86.90B	-103.52B	-106.62B	-106.63B	-107.47B
Gross Profit		248.08B	283.03B	332.24B	391.88B	418.31B
SGA Sales, General & Admin		-163.40B	-180.59B	-214.51B	-248.11B	-267.45B
Op. Income Operating Income		63.88B	82.54B	91.17B	118.21B	125.11B
PBT Profit Before Tax		27.76B	44.81B	94.08B	110.88B	137.52B
Net Income		28.80B	32.73B	84.74B	96.10B	109.29B
Dil. Shares Diluted Shares		2.40B	2.40B	2.40B	2.40B	2.40B
Diluted EPS		12.00	13.60	35.30	39.90	45.60

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Sun Pharma's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Sun Pharma Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		304.42B	348.65B	398.62B	434.33B	526.24B
Non-curr. assets Total non-current assets		372.25B	349.43B	408.82B	420.30B	394.76B
Total assets		676.67B	698.08B	807.44B	854.63B	921.01B
Curr. liabilities Total current liabilities		161.46B	172.08B	199.07B	169.84B	181.95B
Non-curr. liab. Total non-current liabilities		20.41B	15.33B	15.21B	13.73B	14.20B
Total liabilities		181.87B	187.42B	214.28B	183.57B	196.15B
Total equity		494.80B	510.66B	593.15B	671.06B	724.86B
Total liab. & eq. Total liabilities & equity		676.67B	698.08B	807.44B	854.63B	921.01B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Sun Pharma's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Sun Pharma Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		27.99B	44.81B	94.08B	110.88B	137.52B
Operating CF Cash flow Operating Activities		61.70B	89.85B	49.59B	121.35B	140.72B
Capex Investments in PPE		-11.70B	-14.95B	-20.86B	-22.02B	-21.29B
Investing CF Cash flow Investing Activities		5.36B	-57.25B	-79.44B	-6.90B	-53.06B
Dividend Paid		-15.86B	-21.69B	-25.20B	-29.01B	-36.14B
Financing CF Cash flow Financing Activities		-59.80B	-51.93B	23.76B	-67.10B	-79.06B
Cash (start) Cash at beginning of period		56.77B	62.73B	45.08B	46.24B	92.86B
Cash (end) Cash at end of period		62.73B	45.08B	46.24B	92.86B	102.69B
FCF Free Cash Flow		50.00B	74.90B	28.74B	99.33B	119.44B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Sun Pharma's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025